Immunohistochemical Markers of Melanocytic Lesions

Mangini, Janine; Li, Ning; Bhawan, Jag

doi:10.1097/00000372-200206000-00016

Cited by 55 publications

(59 citation statements)

References 129 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Both the MART-1 (melanoma antigen recognized by T cells) and Melan-A antibodies recognize the same gene product and are expressed by normal melanocytes, nevi, and melanoma, but less frequently by DM. 106 HMB-45 (anti-gp100), a premelanosome marker, has been shown to mark the intraepidermal and superficial dermal components of melanocytic nevi, with the exception of diffuse dermal staining in blue nevi. 107 When compared with MART-1, HMB-45 has been found to have weaker and more-focal staining in both primary and metastatic melanomas.…”

Section: Melanocytic Neoplasmsmentioning

confidence: 99%

“…Therefore, HMB-45 is relatively specific, staining only rare other tumors (eg, perivascular epithelioid cells tumors [PEComas]) but is not very sensitive for melanoma. 106,108 MITF is responsible for the normal embryonic development of melanocytes, mast cells, cells of the retinal pigment epithelium, and osteoclasts. 109 Melanocytes express nuclear MITF.…”

Section: Melanocytic Neoplasmsmentioning

confidence: 99%

“…110 However, MITF is not specific, and staining has also been reported in neurofibromas, dermatofibromas, AFX, leiomyosarcomas, schwannomas, malignant peripheral nerve sheath tumors, solitary fibrous tumor, giant cell tumors of the tendon sheath, dermal scars, and granular cell tumors. 106,111 SOX10 (sex-determining region Y-box 10), a nuclear transcription factor expressed in neural crest cells, is crucial for differentiation of Schwann cells and melanocytes. Nuclear staining is noted in normal melanocytes, Schwann cells, secretory cells of the eccrine coil, myoepithelial cells, and predominantly cytoplasmic staining in mast cells.…”

Section: Melanocytic Neoplasmsmentioning

confidence: 99%

“…Increasing expression and thus increasing proliferation is present in malignant melanocytic lesions and is highest in metastatic melanomas. 106 The pattern of staining can also be of assistance. Melanomas reveal MIB-1 staining throughout the lesion, whereas nevi reveal staining superficially, if at all.…”

Section: Benign Versus Malignantmentioning

confidence: 99%

See 3 more Smart Citations

Immunohistochemistry in Dermatopathology

Ferringer

2015

Archives of Pathology &Amp; Laboratory Medicine

View full text Add to dashboard Cite

Context.-Immunohistochemistry is not a diagnostic test but a highly valuable tool that requires interpretation within a context.Objective.-To review the current status and limitations of immunohistochemistry in dermatopathology.Data Sources.-English-language literature published between 1980 and 2014.Conclusions.-Although immunohistochemistry is rarely completely specific or sensitive, it is an important adjunctive technique in dermatopathology and can be helpful in a series of diagnostic dilemmas.

show abstract

Section: Melanocytic Neoplasmsmentioning

confidence: 99%

Section: Melanocytic Neoplasmsmentioning

confidence: 99%

Section: Melanocytic Neoplasmsmentioning

confidence: 99%

Section: Benign Versus Malignantmentioning

confidence: 99%

See 2 more Smart Citations

Immunohistochemistry in Dermatopathology

Ferringer

2015

Archives of Pathology &Amp; Laboratory Medicine

View full text Add to dashboard Cite

show abstract

“…However we see and report cases regularly. Immunohistchemical stains like vimentin, S100 protein, HMB45 and Melan A help us a lot in diagnosis of MM (Mangini et al, 2002;Yaziji and Gown, 2003;de Wit et al, 2004). We use the Clark's system to divide melanomas into levels of invasion (Clark et al, 1969;1979).…”

Section: Dermatopathologymentioning

confidence: 99%

How Our Practice of Histopathology, Especially Tumour Pathology has Changed in the Last Two Decades: Reflections from a Major Referral Center in Pakistan

Ahmad

Idrees²,

Fatima³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Continued advances in the field of histo pathology (and cyto pathology) over the past two decades have resulted in dramatic changes in the manner in which these disciplines are now practiced. This is especially true in the setting of a large university hospital where the role of pathologists as clinicians (diagnosticians), undergraduate and postgraduate educators, and researchers has evolved considerably. The world around us has changed significantly during this period bringing about a considerable change in our lifestyles and the way we live. This is the world of the internet and the world-wide web, the world of Google and Wikipedia, of Youtube and Facebook where anyone can obtain any information one desires at the push of a button. The practice of histo (and cyto) pathology has also evolved in line with these changes. For those practicing this discipline in a poor, developing country these changes have been breathtaking. This is an attempt to document these changes as experienced by histo (and cyto) pathologists practicing in the biggest center for Histopathology in Pakistan, a developing country in South Asia with a large (180 million) and ever growing population. The Section of Histopathology, Department of Pathology and Microbiology at the Aga Khan University Hospital (AKUH) in Karachi, Pakistan's largest city has since its inception in the mid-1980s transformed the way histopathology is practiced in Pakistan by incorporating modern methods and rescuing histopathology in Pakistan from the primitive and outdated groove in which it was stuck for decades. It set histopathology in Pakistan firmly on the path of modernity and change which are essential for better patient management and care through accurate and complete diagnosis and more recently prognostic and predictive information as well.

show abstract

Tumor necrosis factor receptor superfamily member TROY is a novel melanoma biomarker and potential therapeutic target

Spanjaard

Whren

Graves

et al. 2006

Intl Journal of Cancer

Self Cite

View full text Add to dashboard Cite

Incidence of melanoma continues to rise, and a better understanding of its genetics will be critical to improve diagnosis and develop new treatments. Here, we search for novel melanoma-specific genes that may serve as biomarkers and therapeutic targets by using an in vitro genetic screen. One identified cDNA encoded TROY, a member of the tumor necrosis factor receptor superfamily (TNFRSF). TROY is widely expressed during embryogenesis, but in adults expression is restricted to hair follicles and brain. However, TROY had never been associated with melanoma, and it was selected for further study. First we show that expression in melanoma is specific by semiquantitative RT-PCR analysis of a large panel of established tumor cell lines. Next, specificity of expression was evaluated by immunohistochemistry analysis of primary cell cultures and patient tissues. TROY is expressed in 2/2 primary melanoma cells and 45/45 melanoma tissue samples (p < 0.0001). With the exception of sebaceous glands, TROY is not expressed in normal skin biopsies (p < 0.0001) or primary skin cell cultures that contain keratinocytes and epidermal melanocytes, nor is it expressed in other skin tumor cells (p < 0.0001). Finally, we show that TROY regulates melanoma growth, because replication of melanoma cells with reduced TROY levels through treatment with short-interfering RNA was significantly decreased relative to control cells (p < 0.004). In summary, TROY is the first TNFRSF member that is a biomarker for melanoma. TROY also presents a potentially novel cell surface signaling target for inhibitors, cell and/or antibody-based immunotherapies. ' 2006 Wiley-Liss, Inc.

show abstract

Immunohistochemical Markers of Melanocytic Lesions

Cited by 55 publications

References 129 publications

Immunohistochemistry in Dermatopathology

Immunohistochemistry in Dermatopathology

How Our Practice of Histopathology, Especially Tumour Pathology has Changed in the Last Two Decades: Reflections from a Major Referral Center in Pakistan

Tumor necrosis factor receptor superfamily member TROY is a novel melanoma biomarker and potential therapeutic target

Contact Info

Product

Resources

About